Global nuclear medicine firm Curium has joined Progenics Pharmaceuticals in an exclusive agreement to develop and commercialize Progenics' prostate-specific membrane antigen (PMSA)-targeted small molecule PET/CT imaging agent in Europe.
The PSMA-targeted radiopharmaceutical is known as F-18 DCFPyL (PyL). It is designed to visualize bone and soft-tissue metastases and detect the presence of recurrent and/or metastatic prostate cancer.
Under the terms of the deal, Curium will receive an exclusive license to develop and commercialize PyL in Europe. The company will be responsible for development, regulatory approvals, and commercialization of PyL in the region.
In return, Progenics will receive royalties on net sales of the PET agent.
